Quetiapine Fumarate Tablet, Film Coated
NDC Package 33342-101-11
Package Information
Quetiapine Fumarate tablets is a medication used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). This formulation utilizes a tablet, film coated delivery system. Marketed by Macleods Pharmaceuticals Limited, this product is identified by NDC 33342-101 and is authorized under FDA application ANDA203359.
Identification & Billing
- RxCUI: 312743 - QUEtiapine fumarate 100 MG Oral Tablet
- RxCUI: 312743 - quetiapine 100 MG Oral Tablet
- RxCUI: 312743 - quetiapine (as quetiapine fumarate) 100 MG Oral Tablet
- RxCUI: 312744 - QUEtiapine fumarate 25 MG Oral Tablet
- RxCUI: 312744 - quetiapine 25 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 33342 - Macleods Pharmaceuticals Limited
- 33342-101 - Quetiapine Fumarate
- 33342-101-11 - 100 TABLET, FILM COATED in 1 BOTTLE
- 33342-101 - Quetiapine Fumarate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (33342-101). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 33342-101-11 identifies a specific commercial package of 100 tablet, film coated in 1 bottle of Quetiapine Fumarate, a human prescription drug labeled by Macleods Pharmaceuticals Limited. This tablet, film coated is formulated for oral use and contains quetiapine fumarate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Macleods Pharmaceuticals Limited on June 14, 2016. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). Quetiapine is known as an anti-psychotic drug (atypical type). It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. This medication can decrease hallucinations and improve your concentration. It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. It may also improve your mood, sleep, appetite, and energy level. Quetiapine can help prevent severe mood swings or decrease how often mood swings occur.
How is this Macleods Pharmaceuticals Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 33342010111. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.